Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 21;20(3):24.
doi: 10.1007/s11864-019-0619-4.

Current State of Immunotherapy for Treatment of Glioblastoma

Tresa McGranahan  1 , Kate Elizabeth Therkelsen  2 , Sarah Ahmad  2 , Seema Nagpal  2
Affiliations
Review

Current State of Immunotherapy for Treatment of Glioblastoma

Tresa McGranahan et al. Curr Treat Options Oncol. .

Abstract

At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM appears most hopeful for combination of immune therapies to overcome the profound immunosuppression of this disease. Understanding biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM.

Keywords: CAR-T; Checkpoint inhibitors; Glioblastoma; Immunotherapy; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Tresa McGranahan declares that she has no conflict of interest. Kate Elizabeth Therkelsen declares that she has no conflict of interest. Sarah Ahmad declares that she has no conflict of interest. Seema Nagpal has received clinical trial funding from Inovio/Regeneron and Tocagen, has received research support from Nektar Therapeutics, and has received compensation from Nektar Therapeutics for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Zhu P, Du XL, Lu G, Zhu J-J. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget. 2017;8:44015–44031. - PMC - PubMed
    1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. Jama. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed
    1. Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24:1459–1468. doi: 10.1038/s41591-018-0135-2. - DOI - PMC - PubMed
    1. Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York, NY). 2018;362. - PMC - PubMed
    1. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48:812–30.e14. doi: 10.1016/j.immuni.2018.03.023. - DOI - PMC - PubMed